Kairos Return On Equity from 2010 to 2025
| KAPA Stock | 0.74 0.01 1.37% |
Return On Equity | First Reported 2010-12-31 | Previous Quarter (0.55) | Current Value (0.52) | Quarterly Volatility 1.33498167 |
Check Kairos Pharma, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kairos Pharma,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 127.1 K, Interest Expense of 902 K or Selling General Administrative of 1.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.79. Kairos financial statements analysis is a perfect complement when working with Kairos Pharma, Valuation or Volatility modules.
Kairos | Return On Equity | Build AI portfolio with Kairos Stock |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kairos Pharma, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kairos Pharma,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kairos Pharma, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kairos Pharma, Stock:Check out the analysis of Kairos Pharma, Correlation against competitors. For information on how to trade Kairos Stock refer to our How to Trade Kairos Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kairos Pharma,. If investors know Kairos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kairos Pharma, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kairos Pharma, is measured differently than its book value, which is the value of Kairos that is recorded on the company's balance sheet. Investors also form their own opinion of Kairos Pharma,'s value that differs from its market value or its book value, called intrinsic value, which is Kairos Pharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kairos Pharma,'s market value can be influenced by many factors that don't directly affect Kairos Pharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kairos Pharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Kairos Pharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kairos Pharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.